https://dihydroartemisinininhi....bitor.com/single-cou
Outcomes Median followup had been 3.1 years (range, 0.5-10.8 years). In addition, 505 (54.8%) customers had low-risk infection, 236 (25.6%) had positive intermediate-riable safety and efficacy profile, despite variable intrafractional movement management techniques. These conclusions suggest that numerous treatment platforms may be used to safely provide prostate SBRT.Purpose there's absolutely no opinion on how to treat high-risk prostate disease, an